Bates Matzen (cookchair92)

Glucosylceramidase (GCase) is a lysosomal enzyme that catalyzes the cleavage of β-glucosidic linkage of glucocerebroside (GC) into glucose and ceramide; thereby, plays an essential function in the degradation of complex lipids and the turnover of cellular membranes. The growing list of 460 mutations in the gene coding for it-glucosylceramidase beta acid 1 (GBA1)-is reported to abolish its catalytic activity and decrease its enzyme stability, associating it with severe health conditions such as Gaucher disease (GD), Parkinson Disease (PD) and Dementia with Lewy bodies (DLB). Although the three-dimensional structure of wild type glucosylceramidase is elucidated, little is known about its features in human cells. Moreover, alternative sources of GCase that prove to be effective in the treatment of diseases with enzyme treatment therapies, impose the need for a simple and cost-effective procedure to study the enzyme behavior. This work, for the first time, shows a well-established, yet simple, cost- and time-efficient protocol for the study of GCase enzyme in human leukocytes by the artificial substrate p-Nitrophenyl-β-D-glucopyranoside (PNPG). Characterization of the enzyme in human leukocytes for activation parameters (optimal pH, Km, and Vmax) and enzyme inhibition was done. The results indicate that the optimum pH of GCase enzyme with PNPG is 5.0. The Km and Vmax values are 12.6mM and 333 U/mg, respectively. Gluconolactone competitively inhibits GCase, with a Ki value of 0.023 mM and IC50 of 0.047 mM. Glucose inhibition is uncompetitive with a Ki of 1.94 mM and IC50 of 55.3 mM. This is the first report for the inhibitory effect of glucose, δ-gluconolactone on human leukocyte GCase activity.The novel coronavirus (COVID-19) pandemic has emerged disrupting many socio-economical and healthcare aspects across the world. This virus can be transmitted by symptomatic and asymptomatic individuals through saliva and contact. Due to its airborne transmission, aerosols created by natural activities and during dental treatment of infected individuals have become a potential vehicle of transmission and threat. The objective of this review was to assess the existing infection control measures taken in dental health-care settings and suggest modifications to reduce the transmission of novel coronavirus. This is a general review publication. Literature search was made at National Library of Medicine, Pubmed using key words such as "dentistry and COVID", "dentistry and COVID and infection control". Publications related to behaviour, education, ethics, treatment and childcare were excluded. Publications describing general aspects of infection control were reviewed. Keyword "Dentistry and COVID and Infection control" generated 70 publications which were reviewed. Infection control measures in dentistry are designed to minimise cross transmission mainly of blood borne pathogens. The unique nature of COVID-19 including highly infectious and transmissibility, and the ability to survive for a long time in the environment requires special attention and modification to the existing infection control measures which are highlighted here. In conclusion, a modified infection prevention and control (IPC) regime will protect the dental practitioner, assistant and staff, patients and the community. During the pandemic, drastic measures are necessary, however, during an endemic period measures can be remodified as necessary.Spread of multi-drug resistant (MDR) bacteria in natural environments pose a risk to human and animal health. Wild birds are considered to be reservoirs of human pathogens and vectors of antimicrobial resistance distribution in the environment. The aim of this study is to assess the occurrence of antibiotic resistant bacteria in isolates from bird specimens living in three agro-pastoral areas of the southeastern Sicily. We analyzed the microbiomes of the Eurasian Stone curlew Burhinus oedicnemus (Charadriiformes, Aves) and identified 91 G